What are the common complications of aplastic anemia and how are they managed?

Aplastic Anemia Complications and Management

Major Complications

The primary complications of aplastic anemia include life-threatening infections, bleeding, clonal evolution to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and paroxysmal nocturnal hemoglobinuria (PNH), with the risk of clonal complications reaching 57% at 8 years in patients treated with immunosuppressive therapy. 1

Infectious Complications

• Severe neutropenia leads to life-threatening bacterial and fungal infections requiring immediate broad-spectrum antibiotics at fever onset 2
• Short-term G-CSF may be considered during active severe infections in neutropenic patients, though prophylactic use is not recommended as it has not demonstrated survival benefit 2, 3
• Prophylactic antibiotics are not routinely recommended but aggressive treatment of documented infections is mandatory 2

Hemorrhagic Complications

• Thrombocytopenia causes significant bleeding risk, particularly when platelets fall below 50,000/mm³ 2
• Prophylactic platelet transfusions are less commonly used long-term compared to RBC transfusions, except in patients receiving myelosuppressive therapy 2
• Maintain platelet counts at appropriate thresholds based on bleeding risk and clinical status 2

Transfusion-Related Complications

• Chronic transfusion dependence leads to iron overload, affecting multiple organs including the heart 2
• Heart iron overload (MRI T2* <20 ms) is frequent after 70-80 RBC concentrates and associates with decreased left ventricular ejection fraction and heart failure risk 2
• Iron overload before allogeneic stem cell transplantation increases transplant-related mortality, necessitating early chelation in transplant candidates 4, 2

Management approach:

• Transfuse RBCs at hemoglobin threshold of at least 8 g/dL, or 9-10 g/dL in patients with comorbidities worsened by anemia or poor quality of life 2
• Administer sufficient RBC concentrates (over 2-3 days if necessary) to increase hemoglobin >10 g/dL, limiting chronic anemia effects 2
• Initiate iron chelation therapy (preferably oral deferasirox) in patients with favorable prognosis who have received 20-60 RBC concentrates or serum ferritin >1000-2500 U/L 2

Clonal Evolution Complications

The most concerning long-term complication is clonal evolution, which occurs exclusively in patients treated with immunosuppressive therapy, not in those receiving bone marrow transplantation. 1

• Myelodysplastic syndrome or frank leukemia develops in approximately 8% of ALG-treated patients 1
• Paroxysmal nocturnal hemoglobinuria (PNH) occurs in 13% of immunosuppression-treated patients, with 9 of 13 showing clinical hemolysis 1
• The cumulative risk of developing a late hematological complication increases continuously, reaching 57% at 8 years post-immunosuppressive therapy 1
• One patient may develop both PNH and acute leukemia simultaneously 1

Critical monitoring requirement:

• Flow cytometry screening for PNH clones should be performed at diagnosis in all aplastic anemia patients 5
• Only 55.5% of patients undergo appropriate flow cytometry evaluation in real-world practice, representing a significant gap in care 5
• Patients treated with bone marrow transplantation appear cured with no PNH or leukemia development, whereas those treated with immunosuppression remain at lifelong risk 1

Quality of Life Complications

• Chronic anemia causes excess morbidity and cannot be completely corrected by transfusions alone 2
• Psychosocial support and patient support group contacts should be systematically offered 2
• Endocrine dysfunction (thyroid and ovarian hypofunction) represents the most common late complication in transplanted patients 6

Treatment-Specific Complications

Immunosuppressive Therapy Complications

• Viral reactivations are common, particularly before day +180 post-treatment 6
• Delayed treatment initiation (median 22 days from diagnosis) occurs frequently, with older patients (≥40 years) experiencing longer delays 5
• Only 42.6% of identified aplastic anemia patients receive disease-directed therapy in real-world settings 5

Transplant-Related Complications

• Graft rejection and graft-versus-host disease remain concerns, though modern radiation-free conditioning regimens show 100% disease-free survival with minimal GVHD 6
• Infectious disease complications must be controlled before proceeding to allogeneic stem cell transplantation 3
• Pericardial effusion attributed to chronic GVHD occurs in approximately 4.5% of patients 6

Common pitfall: Underutilization of flow cytometry for PNH screening and delayed initiation of appropriate therapy represent major gaps in real-world aplastic anemia management that directly impact complication rates and long-term outcomes 5.